Neurolixis has entered into a strategic collaboration with Jagiellonian University in Kraków (Poland), to synthesize and test novel small molecule therapeutics for the treatment of serious central nervous system disorders such as depression and schizophrenia. These psychiatric disorders affect millions of patients in Europe and North America and constitute a large medical and economic burden. By combining Neurolixis' expertise in drug discovery and development with Jagiellonian University's skills in organic chemistry and pharmacology, the collaborative project will identify new lead candidates for development.

The project will be jointly led by Adrian Newman-Tancredi, Chief Scientific Officer of Neurolixis, and scientists at the Faculty of Pharmacy of Jagiellonian University Medical College, which has a highly recognized research team in the field of psychoses and mood deficits.

Read the full press release:  pdf_symbol

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: